GlaxoSmithKline says it plans on cutting about 650 positions in the United States related to a global restructuring program it announced in July.
The cuts will include about 100 each in offices in Philadelphia and at Research Triangle Park, North Carolina, and 450 sales representatives, a spokesperson said.
According to the drugmaker, the savings from these layoffs will help fund increases in R&D and commercial support of new product launches.
Read the Reuters coverage
[javascriptSnippet]